GeneDx is trading at $59.00, up 5.08% in pre-market, with no clear company-specific catalyst identified for the October 26 move. - GeneDx’s investor-relations release says Q3 2026 results are scheduled for November 9, not October 27 as the earnings-preview headline suggested. - A market snapshot shows a sharp October 23 selloff followed by an after-hours rebound, but does not establish the cause of Monday’s move. - Major index indications were mixed and do not clearly explain the gain.